AI Article Synopsis

  • The study evaluates the use of temporary-permanent pacemakers (TPPM) in patients undergoing transcatheter aortic valve replacement (TAVR) who are at high risk for needing a permanent pacemaker (PPM).
  • Out of 978 TAVR patients analyzed, 111 received TPPM, with 89 included in the final results, showing a median age of 78 and various rates of preexisting heart conditions.
  • Findings suggest that TPPM is a safe and effective pacing method that can help in early recovery and reduce the need for PPM in some cases, with only 1.1% experiencing lead dislodgment and a median hospital stay of 3 days.

Article Abstract

Background: Injury to the cardiac conduction system requiring a permanent pacemaker (PPM) implantation is a known adverse outcome of transcatheter aortic valve replacement (TAVR). Temporary-permanent pacemakers (TPPM) have been used as a bridge to PPM implantation in patients with systemic infection; however, there are only a few reports of its routine use in patients undergoing TAVR. This study aimed to assess the utility of routine use of TPPM in patients undergoing TAVR with a high risk of needing a PPM or those who develop high-grade conduction abnormalities during/after TAVR.

Methods: Between April 2015 and December 2021, 978 patients underwent TAVR at our institution, of whom 111 patients had TPPM placed before or during/after TAVR during the study period. In total, 89 patients were included in the final analysis.

Results: The median age was 78 years (IQR, 71-84 years); 52 (58.4%) patients with preexisting native conduction disease were considered high risk for advanced heart block and had TPPM placed before TAVR. In addition, 37 (41.6%) patients had TPPM placed during/after TAVR. Of the 89 patients who received TPPM, 51 (57.3%) were treated with a balloon-expandable valve and 38 (42.7%) with a self-expandable valve. Of the patients who underwent TPPM placement, only 49 (55.1%) required a PPM, and TPPM was removed in 40 (44.9%) patients. TPPM was in place for a median of 6 days (IQR, 2-11 days). Only 1 of the 89 patients (1.1%) who received a TPPM had lead dislodgment. No other complications were noted. Median length of stay was 3 days (IQR, 2-4 days).

Conclusions: In patients with high-risk baseline conduction abnormalities before TAVR and those who develop new high-grade conduction abnormalities during/after TAVR, TPPM provides a feasible and safe method for pacing that could allow early ambulation, facilitate early discharge, and prevent unnecessary PPM implantations in some patients.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11308022PMC
http://dx.doi.org/10.1016/j.jscai.2024.101310DOI Listing

Publication Analysis

Top Keywords

conduction abnormalities
16
patients
15
patients undergoing
12
patients tppm
12
during/after tavr
12
tppm
11
tavr
9
temporary-permanent pacemakers
8
transcatheter aortic
8
aortic valve
8

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!